<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505750</url>
  </required_header>
  <id_info>
    <org_study_id>2014/14</org_study_id>
    <secondary_id>2014-A01851-46</secondary_id>
    <nct_id>NCT02505750</nct_id>
  </id_info>
  <brief_title>Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma</brief_title>
  <acronym>OPERA</acronym>
  <official_title>European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Haute Energie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Azuréen de Cancérologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Croix-Rousse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de radiothérapie Bayard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oncologie Radiothérapie de Mâcon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Charcot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Cancérologie Lucien Neuwirth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clatterbridge Cancer Centre NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spire Hull and East Riding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Surrey County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm
      using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy
      (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or CXB (90 Gy/3 fractions). The endpoint will be
      organ preservation at 3 years without non-salvageable local pelvic recurrence. The proof of
      this concept will be of most benefit for all patients but especially for the elderly who
      usually are not fit for or keen to undergo major surgery.

      The hypothesis of this study is to determine whether the addition of an endocavitary boost
      with CXB after standard treatment with nCRT, increases the chance of rectum and anus
      preservation by 20%-unites in early rectal adenocarcinoma without locally progressive disease
      (organ preservation in control arm 20%, in experimental arm 40%).

      Main objective To demonstrate that neoadjuvant chemoradiotherapy in combination with a boost
      given with CXB (Arm B) is superior to the same neoadjuvant therapy plus a boost with EBRT
      alone (Arm A) in terms of rectum (organ) preservation without non salvageable local disease
      at 3 years post treatment start, or permanent deviating stoma.

      Study Design Open-label, phase III, prospective, multi-centre, international, randomised 1:1,
      2 arm study designed to evaluate the efficacy of a CXB boost versus an EBRT boost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale - current state of knowledge Current guidelines for cT2-T3 (clinical stage T2 and
      T3) low and middle rectal cancer recommend radical total mesorectal excision (TME) surgery
      that may involves permanent stoma or a low anterior resection with sometimes poor bowel
      function.

      Randomised trials have shown that neoadjuvant (chemo)radiotherapy (nCRT) reduces the risk of
      local recurrence by more than half. At 3 years, it is close to or below 5% with acceptable
      toxicity at many centers. On the other hand, it provides no definite improvement in overall
      survival and does not increase the chances of conservative surgery.

      Rectal adenocarcinoma is rather radioresistant and the dose required to achieve 50%
      sterilization is close to 90 grays (Gy), which is a high dose causing toxicities when given
      with external beam radiation therapy (EBRT). Among the radiotherapy techniques able to
      achieve safely such a high dose, Contact X-Ray Brachytherapy 50 Kv (CXB) is an appealing
      method.

      The Lyon R96-2 randomised trial using CXB showed an increased clinical complete response
      (cCR) rate from 2% to 29% and an improvement by 30% the chance of avoiding a permanent stoma
      (72% vs. 42%). In addition, some patients achieving cCR were able to preserve not only the
      sphincter but the whole rectum (organ preservation) either after local excision or using only
      a &quot;watch and wait&quot; strategy.

      Such a conservative approach is receiving a growing interest all over the world among
      colorectal cancer specialists. The extensive and pioneering work of Prof. Habr Gama in Brazil
      is presently considered as a reference for the use chemoradiotherapy and an EBRT boost (total
      dose 54 Gy/30 f/6 weeks) followed by watch and wait in case of cCR to preserve organ, i.E. to
      avoid surgery.

      Research Hypothesis The investigators propose to conduct a randomised study on cT2, cT3a-b
      tumours less than 5 cm using two different techniques of radiotherapy boost following
      neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or CXB (90 Gy/3
      fractions). The endpoint will be organ preservation at 3 years without non-salvageable local
      pelvic recurrence. The proof of this concept will be of most benefit for all patients but
      especially for the elderly who usually are not fit for or keen to undergo major surgery.

      The hypothesis of this study is to determine whether the addition of an endocavitary boost
      with CXB after standard treatment with nCRT, increases the chance of rectum and anus
      preservation by 20%-unites in early rectal adenocarcinoma without locally progressive disease
      (organ preservation in control arm 20%, in experimental arm 40%).

      Main objective To demonstrate that neoadjuvant chemoradiotherapy in combination with a boost
      given with CXB (Arm B) is superior to the same neoadjuvant therapy plus a boost with EBRT
      alone (Arm A) in terms of rectum (organ) preservation without non salvageable local disease
      at 3 years post treatment start, or permanent deviating stoma.

      Study Design Open-label, phase III, prospective, multi-centre, international, randomised 1:1,
      2 arm study designed to evaluate the efficacy of a CXB boost versus an EBRT boost.

      Randomisation:

      Arm A: 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using
      capecitabine (825 mg/m2 bid, on radiation days).

      A cone down EBRT targeting the Gross Tumour Volume (GTV) will deliver a boost dose of 9 Gy in
      5 fractions. On week 14 after the start of treatment, the tumour response evaluation will
      guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W).

      Arm B divided in 2 subgroups depending on the tumour diameter:

      B1: If the tumour is &lt; 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially
      delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy
      (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on
      radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation
      (week 14) and will guide the final strategy (surgery or W-W) as in arm A.

      B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks)
      with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).

      A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a
      rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will
      guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to
      institution choice.

      Number of subjects: Taking alpha=5% and bêta=7.5% with 10% patients not evaluable after
      randomisation, 236 patients (118 patients/arm) must be enrolled to show a 50% increase in the
      main endpoint at 3 years (from 20% to 40%).This study will show a hazard ratio of 0.56.
      Stopping rule: non-salvageable local recurrence rate &gt; 10% checked by the independent Data
      Monitoring Committee every 80 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>The primary analysis will take place when approximately 138 events have occurred.
The evaluation of the rate of rectum preservation without progressive local disease at 3 years will be performed using a Log rank test stratified by center.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response (assessed by digital rectal examination, endoscopy with photos and MRI)</measure>
    <time_frame>Week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>Time between date of randomisation and date of death due to any causes. Patients who were not reported as having died at the time of the study will be censored at the date they were last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>Time between date of randomisation to time of recurrence, either local or distant metastasis or death due to any cause). Patients without an event will be censored at last date the patient was known to be disease-free. Recurrence of rectal cancer will be based on tumour assessment made by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour regression score on the operative specimen</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of sphincter conservation</measure>
    <time_frame>3 years post treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment toxicity</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>Early and late toxicity by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bowel function</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>Bowel function by modified Low Anterior Resection Score (LARS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>Quality of life questionnaire (QLQ): QLQ-C30 and colorectal (CR) QLQ-CR29 questionnaires</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>EBRT 45 Gy/capecitabine + EBRT boost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).
A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBRT 45 Gy/capecitabine + CXB boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B divided in 2 subgroups depending on the tumour diameter:
B1: If the tumour is &lt; 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.
B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).
A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D conformal EBRT</intervention_name>
    <description>External Beam Radiation Therapy</description>
    <arm_group_label>EBRT 45 Gy/capecitabine + EBRT boost</arm_group_label>
    <arm_group_label>EBRT 45 Gy/capecitabine + CXB boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contact X-ray brachytherapy 50 kV</intervention_name>
    <arm_group_label>EBRT 45 Gy/capecitabine + CXB boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>EBRT 45 Gy/capecitabine + EBRT boost</arm_group_label>
    <arm_group_label>EBRT 45 Gy/capecitabine + CXB boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adenocarcinoma of the rectum classified clinically T2, T3a, T3b (penetration in the
             mesorectal fat between 1 to 5 mm) by TNM classification (Tumour Node Metastase), &lt; 5
             cm largest diameter, &lt; half rectal circumference (by MRI staging), N0-N1 (any node &lt; 8
             mm diameter on MRI), M0

          2. Operable patient

          3. Tumour accessible to endocavitary contact X-Ray Brachytherapy with a distance from the
             lower tumour border to the anal verge ≤ 10cm

          4. 18 years or above

          5. No comorbidity preventing treatment

          6. Adequate birth control

          7. Patient having read the information note and having signed the informed consent

          8. Health care insurance available

          9. Follow-up possible

        Exclusion Criteria:

          1. Inoperable patient

          2. T1, T3cd, T4, T≥ 5cm, T≥ ½ circumference

          3. Patient N2 at diagnosis or N1 with any node &gt; 8 mm diameter

          4. Patient presenting metastasis at diagnosis

          5. Previous pelvic irradiation

          6. Tumour with extramural vascular invasion

          7. Simultaneous progressive cancer

          8. Tumour invading external anal sphincter and within 1 mm, and the levator muscle

          9. Patient unable to receive CXB or CRT

         10. Tumour with poor differentiation (G3)

         11. People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French
             Healthcare Code, including: person deprived of freedom by an administrative or
             judicial decision, adult being the object of a legal protection measure or outside
             state to express their consent, pregnant or breastfeeding women

         12. Any significant concurrent medical illness that in the opinion of the investigator
             would preclude protocol therapy

         13. Patient with history of poor compliance or current or past psychiatric conditions or
             severe acute or chronic medical conditions that would interfere with the ability to
             comply with the study protocol

         14. Concurrent enrolment in another clinical trial using an investigational anti-cancer
             treatment within 28 days prior to the first dose of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine LOVERA</last_name>
    <phone>+33 4 92 03 16 18</phone>
    <email>christine.lovera@nice.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maeva MAURIN</last_name>
    <phone>+33 4 92 03 16 61</phone>
    <email>maeva.maurin@nice.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karen-Lise GARM-SPINDLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soren LAURBERG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Yves MABRUT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christian CARRIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal POMMIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle MARTEL-LAFAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone - AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Didier COWEN, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel RESBEUT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence MOUREAU-ZABOTTO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric TEISSIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie Mâcon</name>
      <address>
        <city>Mâcon</city>
        <zip>71000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicolas BARBET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Haute Energie</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel MORO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier THOMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>René-Jean BENSADOUN, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre GERARD, Prof</last_name>
      <phone>+33 492031260</phone>
      <email>jean-pierre.gerard@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre GERARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen BENEZERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DOYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric FRANCOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrice LORCHEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier CHAPET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guy DE LAROCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MAGNE, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Charcot</name>
      <address>
        <city>Sainte Foy-Lès-Lyon</city>
        <zip>69110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pascale ROMESTAING, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc PAPILLON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CANAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rouge Française - Centre de Radiothérapie St Louis</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas DUBERGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de radiothérapie Bayard</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Régis COQUARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas BARBET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute</name>
      <address>
        <city>Stockolm</city>
        <zip>16 S-11330</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anna MARTLING, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>753 13</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Calin RADU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joakim FOLKESSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexandra STEWART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spire Hull and East Riding Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU10 7AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amandeep DHADDA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Arthur SUN MYINT, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 8RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jamie MILLS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

